Pacira Holders Get $36.50 A Share As Viatris Completes Its Cash Purchase
About 66% of Pacira shares were tendered, and the non-opioid pain-treatment company became a wholly owned Viatris subsidiary.
Viatris completed its purchase of Pacira BioSciences, which develops and sells non-opioid pain treatments, on Tuesday at $36.50 per share in cash. Viatris announced the completed purchase in a company release, bringing Pacira under its full ownership.
Cash For Pacira Shareholders
Viatris accepted 32,929,780 shares for payment, or about 66% of Pacira's outstanding stock, according to its final SEC amendment. The offer drew enough shares to meet its minimum acceptance requirement.
The tender offer expired as scheduled one minute after 11:59 p.m. Eastern Time on Monday. Viatris accepted the tendered shares Tuesday, with payment to follow promptly under the offer's terms.
The merger went through without a Pacira shareholder vote. Shares that holders had not tendered were converted into the right to receive the same cash price, subject to the merger agreement's exceptions, including properly exercised appraisal rights.
EXPAREL Anchors The Pain Business
Pacira's largest product is EXPAREL, a long-acting local anesthetic injection approved for postsurgical pain. Its 2025 sales were $575.1 million, accounting for 79% of total revenue.
The company's other commercial products treat pain through different approaches. ZILRETTA, an extended-release steroid injected into the joint for osteoarthritis knee pain, generated $116.6 million in 2025 sales.
iovera, a handheld device that applies cold to a targeted nerve to relieve pain without drugs, recorded $24.2 million in sales that year. Pacira earns revenue from net sales of those three products.
The Brisbane, California-based company is also developing PCRX-201, a gene therapy in mid-stage trials for knee osteoarthritis. Viatris CEO Scott A. Smith said the combination aims to build a leading position in non-opioid pain management.
Revenue Joins Viatris, Shares Leave Nasdaq
Viatris expects Pacira to contribute $90 million to $100 million in revenue from November 17 through December 31, 2026.
The purchase followed a merger agreement signed October 8 and a tender offer launched October 30. Pacira is now a wholly owned Viatris subsidiary.
Pacira shares will be delisted from the Nasdaq Global Select Market. Viatris and Pacira plan to take steps to deregister the shares with the SEC.
Sources
- SC TO-T/A — Viatris Inc re: Pacira BioSciences, Inc. (PCRX) — SEC EDGAR
- Viatris Completes Acquisition of Pacira BioSciences — prnewswire.com